Preoperative Focused Cardiac Ultrasound in Hip Fracture Surgery (PrEcho)

Sponsor
Umeå University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05862493
Collaborator
(none)
100
2
36

Study Details

Study Description

Brief Summary

The primary objective of this study is to investigate the impact of preoperative focused transthoracic ultrasound (FOCUS) on intraoperative hypotension and postoperative complications in hip fracture surgery. Our hypothesis is that a preoperative FOCUS along with a hemodynamic optimization protocol will reduce the occurrence of intraoperative drops in blood pressure and post-operative complications.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: FOCUS echocardiography
N/A

Detailed Description

Hip fracture surgery is a common procedure, and despite progress in perioperative management, cardiac complications are common, and the post-operative mortality remains high. In this geriatric patient population, cardiac disease as well as varying degrees of dehydration is common, and preoperative knowledge of these conditions have a key role in enabling a proactive perioperative hemodynamic management. However, clinical assessment is surprisingly unreliable and has been shown to easily fail to identify significant cardiac disease and lack of venous return.

Transthoracic echocardiography (TTE) is a well-established and non-invasive investigation that can identify cardiac disease and aberrations in volume status prior to surgery. In a preoperative practice, the use of focused cardiac ultrasound (FOCUS) enables an individualized anesthesia management and has been demonstrated to influence anesthesiologist decision making. Furthermore, measurements of inferior vena cava used as a surrogate for venous return have been shown to be a predictor of intraoperative hypotension.

Patients scheduled for daytime hip fracture surgery will be screened for eligibility.

Random allocation (1:1 allocation ratio) of patients to receive standard care (control group) or standard care + preoperative focused cardiac ultrasound with a preoperative hemodynamic optimization (intervention group). Registration of pre- and intraoperative blood pressure, as well as post-operative complications and mortality will be conducted.

Primary outcome measure: Intraoperative hemodynamic instability defined as MAP < 60 mmHg.Secondary outcome measures: Time to surgery, length of hospital stay, renal failure, cardiac complications (myocardial ischemia, heart failure, post-operative atrial fibrillation, pulmonary edema, pulmonary embolism), 7-,30- and 90-day mortality.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This is a randomized, open label, superiority trial with a 1:1 allocation ratioThis is a randomized, open label, superiority trial with a 1:1 allocation ratio
Masking:
None (Open Label)
Masking Description:
Blinded data analysis
Primary Purpose:
Supportive Care
Official Title:
Preoperative Focused Cardiac Ultrasound in Hip Fracture Surgery - Study Protocol for a Randomized Controlled Trial
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2025
Anticipated Study Completion Date :
Sep 1, 2026

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Standard management

Standard preoperative management, no preoperative TTE

Experimental: FOCUS optimization

Standard preoperative management AND preoperative FOCUS along with an individualized hemodynamic optimization based on FOCUS findings.

Diagnostic Test: FOCUS echocardiography
Preoperative FOCUS echocardiography. Based on FOCUS information: correction of low level of venous return and/or step-up monitoring and/or vasoactive drugs

Outcome Measures

Primary Outcome Measures

  1. Blood pressure drop [From date of randomization up to 4 hours]

    Intraoperative drop in blood pressure defined as mean arterial pressure (MAP) < 60 mmHg

Secondary Outcome Measures

  1. Change of blood pressure level [From date of randomization up to 4 hours]

    Blood pressure (MAP) change from baseline BP

  2. Lowest level of blood pressure (MAP) [From date of randomization up to 4 hours]

    Absolut lowest blood pressure (MAP) from baseline BP

  3. Acute kidney failure [From date of randomization up to 48 hours]

    Acute kidney damage defined as a raise in serum creatinine according to the KDIGO-criteria

  4. Myocardial injury [From date of randomization up to 48 hours]

    Myocardial injury defined as a raise in serum high-sensitive troponin with at least 5 ng/l-1 to a minimum concentration of at least 20 ng/l-1

  5. Readmission [From date of randomization up to 7 days]

    Readmission to hospital within 7 days

  6. Mortality [From date of randomization up to 90 days]

    Postoperative mortality at 7-, 30- and 90-days

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients ≥ 65 years of age, with American Socieity of Anesthesiologists (ASA) physical status classification 2-4, that are scheduled for acute hip fracture surgery (ICD-codes s72.0, s72.00, s72.01, s72.1, s72.2)
Exclusion Criteria:
  • Metastatic cancer and/or suspect pathological fracture.

  • Concurrent other fracture/surgery.

  • Reoperation within 72 hours from primary operation.

  • Severe dementia.

  • Preoperative echocardiography for other reason than participation in the study.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Umeå University

Investigators

  • Principal Investigator: Tomi P Myrberg, MD, PhD, Umeå University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Umeå University
ClinicalTrials.gov Identifier:
NCT05862493
Other Study ID Numbers:
  • Dnr 2022-05628-01
First Posted:
May 17, 2023
Last Update Posted:
May 17, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Umeå University
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 17, 2023